Assessment of Coagulation Factor Levels in Left Ventricular Device (LVAD )Patients Following Temporary Warfarin Reversal With Four Factor Prothrombin Complex Concentrate (4F-PCC) (KVAD)
Assessment of Coagulation Factor Levels in LVAD Patients Following Temporary Warfarin Reversal With 4F-PCC
Sponsor: Brigham and Women's Hospital
Listed as NCT03473132, this PHASE4 trial focuses on Anticoagulation and Anticoagulation Reversal and remains ongoing. Sponsored by Brigham and Women's Hospital, it has been updated 8 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE4
Status: Unknown Status → Unknown
-
May 2023 — Jul 2024 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2021 — May 2023 [monthly]
Recruiting PHASE4
Status: Unknown Status → Recruiting
-
Jan 2021 — Jun 2021 [monthly]
Unknown Status PHASE4
▶ Show 3 earlier versions
-
May 2020 — Jan 2021 [monthly]
Unknown Status PHASE4
Status: Recruiting → Unknown Status
-
Jun 2018 — May 2020 [monthly]
Recruiting PHASE4
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE4
First recorded
Mar 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Brigham and Women's Hospital
- CSL Behring
For direct contact, visit the study record on ClinicalTrials.gov .